Image Place holder

Mihaela Druta, MD

Specialty: Medical Oncology
Program: Sarcoma

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Focus: GIST (Gastrointestinal Stromal Tumor) , Osteosarcoma , Sarcoma

Dr. Druta earned her MD degree from the University of Medicine and Pharmacy Carol Davila, Romainia.  She completed an Internal Medicine Residency and Hematology/Medical Oncology Fellowship at the University of South Florida at Moffitt Cancer Center.  Dr. Druta most recently completed a Sarcoma Medical Oncology Fellowship (Willie Tichenor Sarcoma Fellowship) at MD Anderson Cancer Center. Dr. Druta's clinical interest is in the development of clinical trials focusing on targeted therapeutics specific to sarcoma patients.  Her research interest is in the translational aspects of sarcoma biology focusing specifically on Well-differentiated/Differential Liposarcoma and Leiomyosarcoma.

Education & Training

Board Certification:

  • Internal Medicine
  • Internal Medicine

Fellowship:

  • H. Lee Moffitt Cancer Center - Hematology and Medical Oncology
  • MD Anderson Cancer Center - Sarcoma Medical Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of Medicine and Pharmacy Carol Davilla(MD, - MD)
Participating Trials

CLINICAL TRIAL 19487
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Condition: Sarcoma
Intervention: BMS-936558 (Nivolumab); Nivolumab (); azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18782
A Pilot Study Of NY-ESO-1c259T Cells In Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Condition: Sarcoma
Intervention: NY-ESO-1c259T (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19776
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3021 ()
Open

CLINICAL TRIAL 19414
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec)
Open

CLINICAL TRIAL 20309
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Condition: Sarcoma
Intervention: DCC-2618 (Ripretinib); Sunitinib Malate (SU011248)
Open

CLINICAL TRIAL 20251
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 Study)
Condition: Immunotherapy
Intervention: ADP-A2M4 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19858
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCnyeso, an HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, as a Single Agent in HLA-A*0201 Positive Patients with Advanced NY-ESO-1 and/or LAGE-1A Positive Cancer
Condition: Sarcoma
Intervention: IMCnyeso ()
Open

CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3011 ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 May.9(13):4593-4602. Pubmedid: 32374488.
  • Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract. 2020 Feb. Pubmedid: 32089073.
  • Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 Oct.7(1):276. Pubmedid: 31651363. Pmcid: PMC6813983.
  • Bridge JA, Sumegi J, Druta M, Bui MM, Henderson-Jackson E, Linos K, Baker M, Walko CM, Millis S, Brohl AS. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019 Nov.32(11):1593-1604. Pubmedid: 31189996.
  • Pham V, Henderson-Jackson E, Doepker MP, Caracciolo JT, Gonzalez RJ, Druta M, Ding Y, Bui MM. Practical Issues for Retroperitoneal Sarcoma. Cancer Control. 2016 Jul;23(3):249-264. Pubmedid: 27556665.
  • Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul;112(1):103-106. Pubmedid: 26179670.
  • Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?. Geriatr Oncol. 2014 Jan;5(1):40-48. Pubmedid: 24484717. Pmcid: PMC4527303.
  • Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct;15(4):288-294. Pubmedid: 18813196.
  • Jacobsen PB, Shibata D, Siegel EM, Druta M, Lee JH, Marshburn J, Davenport L, Cruse H, Levine R, Gondi A, Brown R, Malafa M. Measuring quality of care in the treatment of colorectal cancer: the moffitt quality practice initiative. J Oncol Pract. 2007 Mar;3(2):60-65. Pubmedid: 20859375. Pmcid: PMC2793747.

Patient Comments
Overall Satisfaction
4.7

161 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments